Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SpaceX (SPCX) vs Viatris Inc (VTRS) Price & Performance

Viatris IncTrade

Price performance (Past 24H)

Key statistics

SpaceX vs Viatris Inc — how do they compare? SpaceX trades at $160.86 (market cap $2.18T), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: SpaceX is far larger — about 108.8× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while SpaceX pays none. Which is the better fit depends on your goals — on Pluang, investors hold SpaceX for 41 Days and Viatris Inc for 57 Days on average.

SPCXVTRS
Market Cap
$2.18T$20.03B
Volume
68,508,56714,109,977
Sector
IndustrialsHealth
52-Week High
$202.09$18.27
52-Week Low
$108.27$9.74
Typical Hold Time
41 Days57 Days
Enterprise Value
$2.12T$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SpaceX

No Aura AI signal available yet.

Viatris Inc

Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.

The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SPCX
54% Buy46% Sell
Avg holding period · 41 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About SpaceX

SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.

Read more on SPCX →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →